|本期目录/Table of Contents|

[1]吴硕综述,丁留成,卫中庆审校.糖皮质激素受体在去势抵抗性前列腺癌中的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2019,21(4):387-391.[doi:10.3969/j.issn.1672-271X.2019.04.012]
　WU Shuo,reviewing DING Liu-cheng,WEI Zhong-qing.Research progress of GR in Castration-resistant prostate cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2019,21(4):387-391.[doi:10.3969/j.issn.1672-271X.2019.04.012]
点击复制

糖皮质激素受体在去势抵抗性前列腺癌中的研究进展()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第21卷
期数:
2019年4期
页码:
387-391
栏目:
综述
出版日期:
2019-07-20

文章信息/Info

Title:
Research progress of GR in Castration-resistant prostate cancer
文章编号:
1672-271X（2019）04-0387-05
作者:
吴硕综述;  丁留成;  卫中庆审校
作者单位：210011 南京，南京医科大学第二临床医学院外科学系（吴 硕）; 210011 南京,南京医科大学第二附属医院泌尿外科（丁留成、卫中庆）
Author(s):
WU Shuo1; 2;  reviewing DING Liu-cheng1; 2;  WEI Zhong-qing1; 2
(1.Department of Surgery, The Second Clinical Medical College of Nanjing Medical University, 210011 Nanjing, Jiangsu, China; 2.Department of Urology Surgery, Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, Jiangsu, China)
关键词:
糖皮质激素受体;  去势抵抗性前列腺癌;  内分泌治疗新靶点
Keywords:
glucocorticoid receptor;  castration resistant prostate cancer;  endocrine therapy target
分类号:
R730.51
DOI:
10.3969/j.issn.1672-271X.2019.04.012
文献标志码:
A
摘要:
前列腺癌是雄激素依赖类肿瘤,抗雄治疗(ADT)会导致肿瘤进展为去势抵抗性前列腺癌（CRPC）。近期研究发现糖皮质激素受体（GR）在CRPC中存在异常的高表达且与肿瘤的耐药密切相关。GR可在长期ADT治疗的肿瘤中持续激活AR信号通路，维持前列腺癌细胞的增殖和转移。GR作为治疗CRPC的新的药物靶点已经引起广泛关注。文章主要就GR的分子结构，表达水平以及和AR两种转录因子的相似性等角度进行讨论，并对其参与前列腺癌内分泌治疗抵抗的潜在机制进行综述。
Abstract:
Prostate cancer is androgen-dependent tumor. Antiandrogen therapy (ADT) can lead to the progression of cancer to castrated resistant prostate cancer (CRPC). Recent studies have found abnormal high expression of glucocorticoid receptor (GR) in CRPC, which is closely related to drug resistance of tumors. GR can activate AR signaling pathway in tumors with long-term ADT treatment, and maintain the proliferation and metastasis of prostate cancer cells. GR, as a new drug target for CRPC has attracted wide attention. This article mainly elaborates the structure and abnormal expression of GR ,the similarity of AR transcription factors, and the potential mechanism of GR involved in endocrine therapy resistance of prostate cance in order to provide new ideas for the diagnosis and treatment of CRPC.

参考文献/References:

1 AroraVK, SchenkeinE, MuraliR, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade[J]. Cell, 2013, 155(6):1309-1322.
2 SharifiN. Steroid Receptors Aplenty in Prostate Cancer-NEJM[J]. N Engl J Med, 2014, 370(10):970-971.
3 MontgomeryB, ChengHH, DrechslerJ,et al. Glucocorticoids and prostate cancer treatment: friend or foe?[J] Asian J Androl, 2014, 16(3):354-358.
4 MontgomeryB, KheohT, MolinaA, et al. Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301[J]. Eur Urol, 2015, 67(5):866-873.
5 FruchterO, KinoT, ZoumakisE, et al. The human glucocorticoid receptor (GR) isoform {beta differentially suppresses GR{alpha-induced transactivation stimulated by synthetic glucocorticoids[J]. J Clin Endocrinol Metab, 2005, 90(6):3505-3509.
6 VandevyverS, DejagerL, LibertC. Comprehensive overview of the structure and regulation of the glucocorticoid receptor[J]. Endocr Rev, 2014, 35(4):671-693.
7 VandevyverS, DejagerL, LibertC. On the Trail of the Glucocorticoid Receptor: Into the Nucleus and Back[J]. Traffic, 2012, 13(3):364-374.
8 De BosscherK, Vanden BergheW, HaegemanG. The Interplay between the Glucocorticoid Receptor and Nuclear Factor-κB or Activator Protein-1: Molecular Mechanisms for Gene Repression[J]. Endocr Rev, 2003, 24(4):488-522.
9 ChatzopoulouA, RoyU, MeijerAH,et al. Transcriptional and Metabolic Effects of Glucocorticoid Receptor α and β Signaling in Zebrafish[J]. Endocrinology, 2015, 156(5):1757-1769.
10 SchweizerMT, YuEY. Persistent androgen receptor addiction in castration-resistant prostate cancer[J]. J Hematol Oncol, 2015, 8(1):128.
11 PuhrM, HoeferJ, EigentlerA, et al. The glucocorticoid receptor is a key player for prostate cancer cell survival and a target for improved antiandrogen therapy[J]. Clin Cancer Res, 2018， 24:927-938.
12 LamHM, McMullinR, NguyenHM, et al. Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer PatientDerived Xenografts[J]. Clin Cancer Res, 2017，23(9):2301-2312.
13 ClaessensF, JoniauS, HelsenC. Comparing the rules of engagement of androgen and glucocorticoid receptors[J]. Cell Mol Life Sci, 2017, 74(12):2217-2228.
14 DenayerS, HelsenC, ThorrezL, et al. The rules of DNA recognition by the androgen receptor[J]. Mol Endocrinol, 2010，24:898-913.
15 SwinsteadEE, MirandaTB, PaakinahoV, et al. Steroid Receptors Reprogram FoxA1 Occupancy through Dynamic Chromatin Transitions[J]. Cell, 2016, 165(3):593-605.
16 MirandaTB, VossTC, SungMH, et al. Reprogramming the chromatin landscape: interplay of the estrogen and glucocorticoid receptors at the genomic level[J]. Cancer Res, 2013, 73(16):5130-5139.
17 SahuB, LaaksoM, PihlajamaaP, et al. FoxA1 Specifies Unique Androgen and Glucocorticoid Receptor Binding Events in Prostate Cancer Cells[J]. Cancer Res, 2013, 73(5):1570-1580.
18 SahuB, LaaksoM, OvaskaK, et al. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer[J]. EMBO J, 2011, 30(19):3962-3976.
19 ShahN, WangP, WongvipatJ, et al. Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer[J]. eLife, 2017:6.
20 CarverBS. Strategies for targeting the androgen receptor axis in prostate cancer[J]. Drug Discov Today, 2014, 19(9):1493-1497.
21 KassiE, MoutsatsouP. Glucocorticoid receptor signaling and prostate cancer[J]. Cancer Lett, 2011, 302(1):1-10.
22 XieN, ChengH, LinD, et al. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors[J]. Int J Cancer, 2015, 136(4):E27-E38.
23 D'UvaG, LauriolaM. Towards the emerging cross-talk: ERBB family and steroid hormones[J]. Semin Cell Dev Biol, 2016，50:143-152.
24 中华医学会泌尿外科学分会, 中国前列腺癌联盟. 转移性前列腺癌化疗中国专家共识(2017版)[J]. 中华泌尿外科杂志, 2017, 38(3):161-165.
25 KroonJ, PuhrM, BuijsJT, et al. Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer[J]. Endocr Relat Cancer, 2016, 23(1):35-45.
26 ReederA, AttarM, NazarioL, et al. Stress hormones reduce the efficacy of paclitaxel in triple negative breast cancer through induction of DNA damage[J]. Br J Cancer, 2015， 112(9):1461-1470.
27 YemelyanovA, CzwornogJ, ChebotaevD, et al. Tumor suppressor activity of glucocorticoid receptor in the prostate[J]. Oncogene, 2007，26:1885-1896.
28 VenkitaramanR, ThomasK, HuddartRA, et al. Efficacy of low-dose dexamethasone in castration-refractory prostate cancer[J]. Bju International, 2010, 101(4):440-443.
29 MatthewsLC, BerryAA, MorganDJ, et al. Glucocorticoid receptor regulates accurate chromosome segregation and is associated with malignancy[J]. Proc Natl Acad Sci USA, 2015，112(17):5479-5484.
30 SkorMN, WonderEL, KocherginskyM, et al. Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer[J]. Clin Cancer Res, 2013, 19(22):6163-6172.
31 鲍敏,陈海军,毛新良,等.米非司酮衍生物FZU-00,033通过负调控KLF5表达抑制三阴性乳腺癌的生长[J].医学研究生学报,2018,31(6):608-612.
32 KachJ, LongTM, SelmanP, et al. Selective glucocorticoid receptor modulators (SGRMs) delay castrate-resistant prostate cancer growth[J]. Mol Cancer Ther,2017, 16:1680-1692.
33 KachJ, ConzenSD, SzmulewitzRZ. Targeting the glucocorticoid receptor in breast and prostate cancers[J]. Sci Transl Med, 2015, 7(305):305ps19.
34 夏正坤.糖皮质激素临床应用再认识[J].医学研究生学报,2018,31(2):113-117.

相似文献/References:

[1]刘 瑜,方 放,黄 方.糖皮质激素受体基因多态性与脓毒症临床转归的相关性研究[J].医学研究与战创伤救治(原医学研究生学报),2015,17(06):575.[doi:10.3969/j.issn.1672-271X.2015.06.005]
　LIU Yu,FANG Fang,HUANG Fang..Association of polymorphisms in glucocorticoid receptor with outcome of sepsis in a Chinese Han population[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(4):575.[doi:10.3969/j.issn.1672-271X.2015.06.005]

备注/Memo

备注/Memo:
收稿日期：2019-01-10
更新日期/Last Update: 2019-07-11